BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) SVP Chan Henry Lee sold 428 shares of BeOne Medicines stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $257.63, for a total transaction of $110,265.64. Following the sale, the senior vice president owned 346,554 shares in the company, valued at approximately $89,282,707.02. The trade was a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Chan Henry Lee also recently made the following trade(s):
- On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.
- On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04.
- On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total transaction of $103,447.88.
BeOne Medicines Trading Down 0.5%
BeOne Medicines stock opened at $262.68 on Thursday. The stock has a market cap of $28.82 billion, a P/E ratio of 58.77 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $239.25 and a 1 year high of $385.22. The firm’s 50 day moving average price is $296.83 and its 200-day moving average price is $312.94.
Institutional Trading of BeOne Medicines
Large investors have recently made changes to their positions in the business. Cetera Investment Advisers bought a new position in BeOne Medicines during the second quarter valued at $455,000. Rhumbline Advisers bought a new position in BeOne Medicines during the second quarter valued at $275,000. Arrowstreet Capital Limited Partnership bought a new position in BeOne Medicines during the second quarter valued at $505,000. Invesco Ltd. bought a new position in BeOne Medicines during the second quarter valued at $422,000. Finally, EverSource Wealth Advisors LLC bought a new position in BeOne Medicines during the second quarter valued at $68,000. 48.55% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Barclays boosted their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Truist Financial reissued a “buy” rating and issued a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Wells Fargo & Company started coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Finally, Jefferies Financial Group downgraded shares of BeOne Medicines from a “buy” rating to a “hold” rating and reduced their target price for the stock from $420.00 to $290.00 in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.
Read Our Latest Analysis on ONC
BeOne Medicines Company Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Stories
- Five stocks we like better than BeOne Medicines
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
